Furthermore, combining crizotinib with immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed cell death-1 ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) show potential for NSCLC treatment. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.